Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07620548 · ClinicalTrials.gov registry record · Phase 2
Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas
A Phase 2 study, sponsored by Washington University School of Medicine.
- Not yet
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
NCT07620548 is a Phase 2 study that has not yet begun recruiting, run by Washington University School of Medicine. The registered enrollment target is 99 participants.
The verdict
NCT07620548, a Phase 2 study, has not yet begun recruiting, sponsored by Washington University School of Medicine.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
Study Summary
This study will assess the therapeutic efficacy of the combination of Laser Interstitial Thermal Therapy (LiTT) with adjuvant cemiplimab compared to the therapeutic efficacy of the combination of LiTT with physician's choice of adjuvant chemotherapy in patients with recurrent glioblastoma. Patients will be enrolled and randomized on a 2:1 ratio to either the experimental arm (LiTT + cemiplimab) or the control arm (LiTT + physician/s choice chemotherapy).
Interventions
- DRUG Cemiplimab
- DRUG Chemotherapy
- DEVICE NeuroBlate® Laser Ablation Laser Interstitial Thermal Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2026-08-31 |
| Est. Completion | 2032-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07620548
The ClinicalTrials.gov registry entry for NCT07620548 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cemiplimab is the first listed.
NCT07620548 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07620548 about?
NCT07620548 is a clinical study titled "Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas". This study will assess the therapeutic efficacy of the combination of Laser Interstitial Thermal Therapy (LiTT) with adjuvant cemiplimab compared to the therapeutic efficacy of the combination of LiTT with physician's choice of adjuvant chemotherapy in patients with recurrent glioblastoma. Patients ...
What is the current status of trial NCT07620548?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2026-08-31. Estimated completion is 2032-08-31.
What interventions are being tested in trial NCT07620548?
The interventions under investigation include: Cemiplimab (DRUG), Chemotherapy (DRUG), NeuroBlate® Laser Ablation Laser Interstitial Thermal Therapy (DEVICE).
Who is sponsoring clinical trial NCT07620548?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.